# Single Dose Glumetinib in Healthy Chinese Male Subjects

> **NCT05507294** · PHASE1 · COMPLETED · sponsor: **Haihe Biopharma Co., Ltd.** · enrollment: 18 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Glumetinib

## Key facts

- **NCT ID:** NCT05507294
- **Lead sponsor:** Haihe Biopharma Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-02
- **Primary completion:** 2021-05-21
- **Final completion:** 2021-09-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05507294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05507294, "Single Dose Glumetinib in Healthy Chinese Male Subjects". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05507294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*